ABSTRACT
This work builds on pilot studies reported herein, carried out in collaboration with James C. Yang, M.D. and Christopher J. Bartels, M.D., under the direction of Stephen S. Rosenberg, M.D., Surgery Branch, National Cancer Institute, National Institutes of Health (NCI/NIH). Having established in related work that the controlled release of a number of traditional drugs and new biologicals are amenable to our proprietary formulation methods, we next will address the manipulation of processing parameters as a means of establishing uniform 2-to 3-week release of IL-2. Our pilot studies have shown that our injectable controlled release IL-2 system provides for substantial time periods of bioactive IL-2 release ranging from days to weeks. This 2-to 3-week system for cancer treatment clearly will alleviate significant problems in the logistics of using TILs and thereby “manually” enhancing the immune response to cancerous tumors.
